ARTICLE | Company News
Napo, Trine Pharmaceuticals deal
February 18, 2008 8:00 AM UTC
Trine returned to Napo rights to crofelemer after preliminary data from a Phase IIb trial to treat diarrhea-predominant irritable bowel syndrome (IBS) showed that the oligomeric proanthocyanidin misse...